Lyell Immunopharma Inc.

NASDAQ: LYEL · Real-Time Price · USD
10.62
-0.14 (-1.30%)
At close: Aug 15, 2025, 3:59 PM
10.58
-0.38%
After-hours: Aug 15, 2025, 04:10 PM EDT

Lyell Immunopharma Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
61K 130K 84.68M 10.65M
Cost of Revenue
n/a n/a 16.47M 14.54M
Gross Profit
61K 130K 68.22M -3.88M
Operating Income
-358.75M -247.01M -183.12M -214.78M
Interest Income
24.07M 23.45M 7.05M 1.17M
Pretax Income
-342.99M -234.63M -183.12M -250.22M
Net Income
-342.99M -234.63M -4.75M -285.5M
Selling & General & Admin
52.04M 66.98M 117.31M 89.06M
Research & Development
171.6M 182.94M 159.19M 138.69M
Other Expenses
135.17M -2.79M 1.89M -2.32M
Operating Expenses
358.82M 247.14M 276.5M 225.43M
Interest Expense
n/a n/a n/a n/a
Selling & Marketing Expenses
n/a n/a n/a n/a
Cost & Expenses
358.82M 247.14M 276.5M 225.43M
Income Tax Expense
n/a n/a -178.36M 35.28M
Shares Outstanding (Basic)
261.48M 250.98M 247.08M 242.74M
Shares Outstanding (Diluted)
261.48M 250.98M 247.08M 242.74M
EPS (Basic)
-1.31 -0.93 -0.74 -1.03
EPS (Diluted)
-1.31 -0.93 -0.74 -1.03
EBITDA
-200.64M -226.76M -166.65M -199.94M
EBIT
-220.27M -247.01M -187.06M -214.78M
Depreciation & Amortization
19.63M 20.25M 16.47M 14.54M